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and prescriptions were summarized in natural units. Average
(95%CI) outpatient, inpatient and drug cost/patient for EBC
patients were estimated to be €1000 (780–1260), €1060 (800–
1300) and €2470 (2100–2840) respectively. For LRR patients the
corresponding ﬁgures were €274 (214–330), €2056 (1470–2600)
and €2160 (1600–2700). In MBC values averaged €260
(210–310), €1150 (850–1550) and €3470 (2800–4150) respec-
tively. Drug costs represented 23%, 40% and 29% of total treat-
ment costs/patient in EBC, LRR and MBC. Costs were highest
in MBC. CONCLUSIONS: Inpatient costs represent the highest
proportion of costs, followed closely by drug costs, possibly due
to relatively low labour costs in Central Europe. These estimates
and underlying treatment patterns will be useful in establishing
the cost-effectiveness of new BC treatments in Hungary and
potentially in the region.
OSTEOPOROSIS & ARTHRITIS
OA1
QUALITY OF LIFE IN EARLY RHEUMATOID ARTHRITIS
TREATED WITH COMBINATION VS. SINGLE DRUG
THERAPY—RESULTS FROM FIN-RACO TRIAL
Hahl J1, Bergius S1, Sintonen H2, Hannonen P3, Korpela M4,
Leirisalo-Repo M5, Hakala M6, Möttönen T7
1GlaxoSmithKline Oy, Espoo, Finland, 2University of Helsinki, Helsinki,
Finland, 3Jyväskylä Central Hospital, Jyväskylä, Finland, 4Tampere
University Hospital,Tampere, Finland, 5Helsinki University Central
Hospital, Helsinki, Finland, 6Rheumatism Foundation Hospital, Heinola,
Finland, 7Turku University and Turku University Central Hospital,
Paimio, Finland
The Finnish rheumatoid arthritis (RA) combination therapy
(FIN-RACo) trial has shown better efﬁcacy of three disease-
modifying antirheumatic drugs (DMARD) (sulphasalazine,
methotrexate, hydroxychloroquine) and prednisolone compared
to treatment with a single DMARD with or without pred-
nisolone in early RA. Results from FIN-RACo trial show that
early aggressive combination therapy (COMBI) translated into
more remissions and less peripheral joint damage, cervical spine
subluxations, and work disability than therapy with a single
DMARD (SINGLE). OBJECTIVES: Estimate health-related
quality of life (HRQoL) effects of COMBI vs. SINGLE in early
RA. METHODS: A total of 195 patients with early RA were
randomised to COMBI (n = 97) or SINGLE (n = 98) for 2 years.
Thereafter drug treatment became unrestricted. HRQoL was
measured using the 15D instrument. The 15D score of an addi-
tional control sample was used as an estimate of baseline
HRQoL in early RA. RESULTS: The baseline 15D score was
0.856 (95% CI 0.835–0.877; n = 49). The respective ﬁve and
10–11 years 15D scores of COMBI were signiﬁcantly better than
the baseline score (0.929; n = 28, p = 0.000 and 0.901; n = 39,
p = 0.002), in contrast to the corresponding scores of SINGLE
(0.880; n = 34, p = 0.078 and 0.858; n = 30, p = 0.900). The
differences between the COMBI and SINGLE scores at 5 and
10–11 years reached statistical signiﬁcance (p = 0.017 and
0.046), too. CONCLUSION: Early aggressive treatment with
combination of DMARDs is effective also from the viewpoint of
HRQoL. The effect sustains at least up to 10–11 years.
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OBJECTIVES: To evaluate whether it is accepted that commu-
nity pharmacies identify elderly people which are at risk for
osteoporosis and furthermore evaluate the effectiveness of com-
munity pharmacies to motivate identiﬁed patients at risk for
osteoporosis to consult a physician for further diagnosis and
treatment. METHODS: Prospective multi-centre pre-post evalu-
ation in 20 community pharmacies in Southern Germany includ-
ing 765 patients. The screening for risk for osteoporosis 
was based on an adapted osteoporosis risk-questionnaire of 
the “Kuratorium Knochengesundheit e.V.—German Self-Help-
Group”. Patients with identiﬁed risk were consulted with regard
to the disease osteoporosis and recommended to see a physician
for further diagnosis. A maximum of 2 follow-up contacts were
undertaken to receive information whether or not a physician
was seen by the patient. RESULTS: Out of 765 patients, which
were interviewed using the osteoporosis risk-questionnaire 53%
were identiﬁed being at risk and thus were requested to contact
their physician. 66% of these patients did respond to the rec-
ommendation by the community pharmacy and did see a physi-
cian for consultation and further diagnosis of osteoporosis. As a
result, an anti-osteoporotic pharmacotherapy was initiated in
33% of those patients who saw a physician. Overall, 57% of
patients indicated their satisfaction with the service provided by
the pharmacy and 64% agreed that a community pharmacy is
an appropriate place to offer screening for osteoporosis. CON-
CLUSION: Community pharmacies are easy to access by elderly
people and a screening for osteoporosis using an osteoporosis
screening risk-questionnaire was accepted by the majority of
patients.
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OBJECTIVES: How GPs reacted to rofecoxib withdrawal in
Sept. 30, 2004. METHODS: A drug utilisation review was 
performed using data from the electronic records of 1200 French
GPs. All patients aged 65 years and over, suffering from
osteoarthritis and who were prescribed any COX-2 between
January 1st and September 30th 2004 (“reference period”) were
included and compared to themselves in the same period of 2005
(“observation period”). Patients were classiﬁed either as “con-
tinuers” if they received at least one COX-2 prescription in the
“observation period”, or as “stoppers” if not. Discriminatory
factors between the two groups were systematically searched for.
RESULTS: A total of 5589 patients were included. Mean age was
75 years and 68.2% were female. A total of 811 (14.5%) were
classiﬁed as “continuers” and 4778 (85.5%) as “stoppers”.
Among the latter 2914 (61.0%) stopped any NSAID treatment
and 955 (19.9%) received no treatment at all (neither NSAID
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nor paracetamol or aspirin). There were a majority of “stoppers”
even among those who previously received celecoxib (53.4%).
The proportion of patients with long term COX-2 treatment (3
months or over) was higher in the “continuers” group (23.9%
vs. 13.7%; p < 0.001). Conversely, patients with history of stroke
(4.2% vs. 2.6%; p = 0.026) or coronary heart disease (14.7%
vs. 11.5%; p = 0.015) and with a higher risk of gastrointestinal
events (50.7% vs. 43.2%; p < 0.0001) were in greater propor-
tion in the “stoppers” group. Finally, the percentage of NSAID
treated patients receiving a proton pump inhibitor raised sub-
stantially from 37.1% to 72.0% (p < 0.001) between the two
periods. CONCLUSIONS: French GPs reacted in a non selective
way, making little difference between rofecoxib and celecoxib,
and between cardiovascular and gastrointestinal risks. This
unexpected behaviour may be interpreted as a concern toward a
reduction of any kind of risk and not only those targeted by the
withdrawal decision.
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OBJECTIVES: Chronic low-back pain related to osteoarthritic
changes of the lumbar spine has a signiﬁcant economic impact
on health care budgets worldwide. Anterior-Lumbar-Interbody-
Fusion (ALIF) surgery can be an effective treatment option after
non-operative therapy fails. Frequently, the affected vertebrae are
fused together using bone (autograft) from patient’s hip, which
requires additional surgery and leads to increased co-morbidity,
blood loss, infection rate, and pelvic instability. We assessed the
cost-effectiveness of rhBMP-2 compared with autograft in spine
fusion surgery over two years from a health care payer’s per-
spective in Germany and UK. METHODS: An economic model
was developed to evaluate differences in the two-year results
between spine-fusion surgery with rhBMP-2 and fusion with
bone autograft. The cost and health-related quality-of-life asso-
ciated with both arms were estimated for two years after surgery.
Data were obtained from a previously published analysis of
pooled data, in which patients in the rhBMP-2 arm showed sig-
niﬁcant clinical improvements after surgery compared to stan-
dard therapy. Cost data were obtained from German-DRGs 
and UK NHS and are reported in 2005 values. RESULTS: In
Germany, signiﬁcant reduction in secondary interventions, and
better fusion rates associated with rhBMP-2 treatment resulted
in faster return to work and generated savings of €3453 per
patient for health care insurances, leading to net savings of €503
per patient. These savings offset the upfront prize of €2950 for
rhBMP-2 therapy. In the UK, the beneﬁts of use of rhBMP-2 lead
to an incremental cost-effectiveness ratio of GBP 5483/QALY
(€8039/QALY) for the NHS. CONCLUSIONS: The standard use
of rhBMP-2 in ALIF surgery lowers costs for surgically treated
patients with degenerative changes of the lumbar spine in
Germany and is a cost-effective treatment option in the UK.
RESPIRATORY DISORDERS
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OBJECTIVES: Clinical practice guidelines have been shown 
to improve medical practice. However the place of the reps to
improve compliance with guidelines initiated by state agencies
(HAS, AFSSAPS) has not been evaluated. The study has been ini-
tiated by several pharmaceutical industries involved in research.
METHODS: Two intervention studies were used to provide evi-
dence of the effectiveness of the reps visits on the physician prac-
tice. During their visit, the reps gave a written document. The
written document was a validated and synthesized version of a
guideline initiated by state agencies. The subjects of the guide-
lines were asthma or migraine. The ﬁrst intervention study eval-
uated the physicians’ perception of the reps’ intervention. The
second study evaluated the physicians’ knowledge. For the ﬁrst
study, the study material was a questionnaire (12 questions) and
the study was conducted by phone. For the second study, the
study material was an internet based questionnaire (40 ques-
tions) which follows the content of the written document given
by the reps to the physicians. A score was constructed to evalu-
ate the level of knowledge of the physicians. RESULTS: For the
ﬁrst study: 800 physicians have been included. 81% (82%) ﬁnd
the intervention of the reps useful and 76 % (81%) legitimate
the guidelines for asthma (migraine). For the second study: 294
physicians have been included. The level of knowledge was sig-
niﬁcantly higher for asthma after the reps’ visit (16.37/14.44)
and for the physician who conserved the written document. No
signiﬁcant results were found for migraine. CONCLUSION:
The reps can be another way to diffuse the clinical practice 
guidelines.
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OBJECTIVES: Inhaled corticosteroids (ICS) are the cornerstone
of asthma-treatment. Yet, adherence with ICS-treatment is very
low. Therefore, the aim of the study was to investigate adher-
ence, in terms of persistent use, with ICS and its determinants in
asthma-patients. METHODS: The PHARMO database includes,
among others, drug-dispensing and hospital discharge records
for >2 million subjects in The Netherlands. All asthma-patients
(age <35 yrs) with a ﬁrst prescription for ICS in 1999–2002 and
≥2 prescriptions in the ﬁrst year were included in the study. Per-
sistence during the ﬁrst year was deﬁned as the number of days
from start to time of ﬁrst failure to continue renewal of the initial
ICS, and ascertained based on the method of Catalan. Potential
determinants of persistence were assessed at ICS-start and one-
year before. RESULTS: The study-cohort included 5563 new
users of single ICS and 297 of ﬁxed combined ICS. Less than
10% of patients using single ICS, and 15% of patients using
ﬁxed combined ICS were persistent at one year. Increased 
persistence with single ICS was observed with type of ICS 
(budesonide), prescriber (specialist), prior use of long-acting
beta-agonists, previous hospitalization for asthma, metered-dose
inhaler, low starting dose, and once-daily dosing regimen at start.
Decreased persistence with ﬁxed combined ICS-treatment was
found in patients having high starting dose of ICS and prior use
of antibiotics. CONCLUSIONS: Persistence with ICS-treatment
for asthma in clinical practice is low for both single and ﬁxed
combined ICS-treatment. Persistence was mainly related to
patient-factors, such as severity of disease, and to treatment-
related factors, such as once-daily dosing frequency and low dose
